Structure via PubChem · Public domain (PubChem)
dolutegravir
Sign in to saveAlso known as GSK 1349572, GSK-1349572, GSK1349572, S-349572, S/GSK1349572
Dolutegravir (DTG), sold under the brand name Tivicay or Instgra, is an antiretroviral medication used, together with other medication, to treat HIV/AIDS. It may also be used, as part of post exposure prophylaxis, to prevent HIV infection following potential exposure. It is taken by mouth.
Chemical data
- Formula
- C20H19F2N3O5
- Molecular weight
- 419.4 g/mol
- IUPAC name
- (3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-13-carboxamide
- SMILES
- C[C@@H]1CCO[C@@H]2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O
- InChIKey
- RHWKPHLQXYSBKR-BMIGLBTASA-N
- XLogP
- 2.4
- Polar surface area
- 99.2 Ų
- H-bond donors
- 2
- H-bond acceptors
- 8
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2013
- Admin. routes
- oral
- Indications
- viral disease, HIV infection, HIV-1 infection, AIDS
via ChEMBL · EBI
Research
3,167 papers- Dolutegravir-associated hyperglycemia: a narrative review.AIDS research and therapy · 2025
- HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis.The lancet. HIV · 2023
- Dolutegravir/Lamivudine Single-Tablet Regimen: A Review in HIV-1 Infection.Drugs · 2020
- Predictors of treatment-emergent resistance to dolutegravir.The lancet. HIV · 2025
- Dolutegravir/Rilpivirine: A Review in HIV-1 Infection.Drugs · 2018
via PubMed
Wikidata facts
- Mass
- 419.129
- Has use
- medication
Show 8 more facts
- chemical formula
- C₂₀H₁₉F₂N₃O₅
- World Health Organisation international non-proprietary name
- dolutegravir
- isomeric SMILES
- C[C@@H]1CCO[C@@H]2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O
- canonical SMILES
- CC1CCOC2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O
- Commons category
- Dolutegravir
- defined daily dose
- 50
- subject has role
- essential medicine
- medical condition treated
- HIV infection
Sources (7)
via Wikidata · CC0
~6 min read
Encyclopedic overview
7 sectionsContents
- Medical use
- Adverse effects
- Pregnancy
- History
- Access
- Climate change
- References
Dolutegravir (DTG), sold under the brand name Tivicay or Instgra, is an antiretroviral medication used, together with other medication, to treat HIV/AIDS. It may also be used, as part of post exposure prophylaxis, to prevent HIV infection following potential exposure. It is taken by mouth.
Common side effects include trouble sleeping, feeling tired, diarrhea, high blood sugar, and headache. Severe side effects may include allergic reactions and liver problems. Concerns that usage during pregnancy can result in harm to the baby have been refuted by further studies that show there is no statistical difference in neural tube defects from the usage of dolutegravir compared to other antiretrovirals. It is unclear if use during breastfeeding is safe. Dolutegravir is an HIV integrase strand transfer inhibitor which blocks the functioning of HIV integrase which is needed for viral replication.
Excerpted from Wikipedia’s “dolutegravir” article, available under the CC BY-SA 4.0 licence.